FDG-PET/MRI在结直肠癌及肛管癌中的应用更新
本文综述了FDG-PET/MRI在结直肠癌和肛管癌中的近期文献,指出全身FDG-PET/MRI结合了分子成像与优异软组织对比,在初始诊断、局部治疗反应评估及转移评估中有潜在价值。文章还提供了全身FDG-PET/MRI协议示例,强调了判读陷阱,并针对特定临床场景给出了推荐。
要点
- FDG-PET/MRI可整合分子成像与高软组织分辨率,用于结直肠癌和肛管癌的初始诊断与转移评估。
- 判读时需注意生理性肠道FDG摄取等陷阱,避免误判。
- 在局部治疗反应评估及特定临床场景中,FDG-PET/MRI可能较标准解剖成像更有优势。
关键影像表现/征象
- FDG-PET/MRI将分子成像与优异的软组织对比分辨率相结合,可改善下消化道恶性肿瘤的成像。
- 既往分子成像在下消化道肿瘤中应用受限,部分原因是伴随CT的解剖评估欠佳以及肠道显著的生理性18F-FDG摄取。
临床应用与阅片要点
- FDG-PET/MRI可用于结直肠癌和肛管癌的初始诊断、局部治疗反应评估及转移评估。
- 判读时需警惕生理性肠道FDG摄取等陷阱,避免将其误判为病变。
- 针对特定临床场景,FDG-PET/MRI可能较PET/CT或MRI更有益,应根据场景合理选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Positron emission tomography (PET) in the era of personalized medicine has a unique role in the management of oncological patients and offers several advantages over standard anatomical imaging. However, the role of molecular imaging in lower GI malignancies has historically been limited due to suboptimal anatomical evaluation on the accompanying CT, as well as significant physiological 18F-flurodeoxyglucose (FDG) uptake in the bowel. In the last decade, technological advancements have made whole-body FDG-PET/MRI a feasible alternative to PET/CT and MRI for lower GI malignancies. PET/MRI combines the advantages of molecular imaging with excellent soft tissue contrast resolution. Hence, it constitutes a unique opportunity to improve the imaging of these cancers. FDG-PET/MRI has a potential role in initial diagnosis, assessment of local treatment response, and evaluation for metastatic disease. In this article, we review the recent literature on FDG-PET/MRI for colorectal and anal cancers; provide an example whole-body FDG-PET/MRI protocol; highlight potential interpretive pitfalls; and provide recommendations on particular clinical scenarios in which FDG-PET/MRI is likely to be most beneficial for these cancer types.
引用
- Jayaprakasam, Ince, Suman, et al. PET/MRI in colorectal and anal cancers: an update. Abdom Radiol (NY). 2023. PMID: 37062021. doi:10.1007/s00261-023-03897-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。